Once-Weekly Hypofractionated Radiotherapy for Breast Cancer in Elderly Patients : Efficacy and Tolerance in 486 Patients
Sanz, Javier (Universitat Pompeu Fabra)
Zhao, Min (Universitat Autònoma de Barcelona)
Rodríguez, Nuria (Universitat Pompeu Fabra)
Granado, Raquel (Hospital del Mar (Barcelona, Catalunya))
Foro, Palmira (Universitat Pompeu Fabra)
Reig, Ana (Hospital del Mar (Barcelona, Catalunya))
Membrive, Ismael (Hospital del Mar (Barcelona, Catalunya))
Algara, Manuel (Universitat Pompeu Fabra)

Fecha:	2018
Resumen:	Radiation therapy is a key treatment of breast cancer. Elderly patients with associated diseases that modify their performance status do not tolerate long periods of daily irradiation. The objective of this study is to analyze the results of weekly hypofractionated treatment in these patients. Between 1992 and 2016, we included 486 elderly patients presenting concomitant pathology or sociofamilial problems in which it was not feasible to propose conventional treatment. They were treated with conservative surgery or mastectomy and then adjuvant hypofractionated irradiation, administering 5 Gy or 6. 25 Gy in 6 fractions, once a week (total dose 30-37. 5 Gy) over 6 weeks. Breast cancer overall survival according to the Kaplan-Meier method at 5 years was 74. 2% ± 2. 3%; breast cancer disease-free survival was 90% ± 1. 6%; local relapse-free survival was 96. 5% ± 1% showing that patients die more from other causes and not from their neoplasia. Acute dermatitis was mild (75. 6% of the patients grades I-III) and 30. 6% had moderate chronic fibrosis. The once-weekly hypofractionated radiotherapy is a feasible and convenient option for elderly patients with breast cancer. It is a safe treatment modality with similar survival and local control results compared to standard fractionation, while the side effects are acceptable.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Publicado en:	BioMed Research International, Vol. 2018 (march 2018) , ISSN 2314-6141

DOI: 10.1155/2018/8321871
PMID: 29736399

9 p, 1.3 MB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados